Skip to main content

Table 1 Major laboratory results according to 03 cycles since sunitinib administration for 28 months

From: When tyrosine kinase inhibitor sunitinib can be discontinued in metastatic renal cell carcinoma to pancreas: a case report

Parameter May 2014 August 2014 November 2014 February 2015 May 2015 August 2015 November 2015 February 2016 May 2016 September 2016
Hb (g/dL) 14.2 13.3 13.5 13.7 13.2 13.6 13.9 14.1 13.8 13.9
WBC (× 109/L) 4.89 4.10 5.02 4.67 4.90 5.15 4.77 4.07 5.08 4.78
PLT (× 109/L) 205 198 175 189 176 154 132 120 115 120
TB (umol/L) 3 2 3 3       
ALT (U/L) 16 19 20 14 19 21 22 16 15 14
AST (U/L) 12 11 13 13 14 13 15 17 13 11
BUN (g/L 0.25 0.25 0.32 0.40 0.4 0.42 0.42 0.39 0.31 0.43
BCr (mg/L) 11 11 12 11 9 10 11 11 10 11
Proteinuria 0 0 0 0 0 0 0 0 0 0
TSH (microUI/mL) 1.34 2.09 2.98 3.34 6.02 19.16 15.68 9.45 7.45 5.69
  1. Normal ranges are given in parentheses as follows: Hb hemoglobin, WBC white blood cell (4.0–10.0 × 109/L), PLT platelet (100–300 × 109/L), TB total bilirubin (1.7–22.5 μmol/L), ALT alanine aminotransferase (5–45 U/L), AST aspartate aminotransferase (5–45 U/L), BUN blood urea nitrogen (0.17–0.49 g /L), BCr Blood creatinine (7–12 mg/L), TSH thyroid-stimulating hormone (0.27–4.20 microUI/mL)